Mobilized allogeneic PBPC are increasingly used instead of BM for allogeneic stem cell grafting. Although the short-term safety profile of recombinant human (rh)G-CSF seems acceptable, only minimal data on long-term safety are available. We therefore reviewed data on 171 sibling donors (M/F: 98/73) with respect to side effects of rhG-CSF and PBPC collection and impact on quality of life (QoL) and health status. In a cross-sectional study, we investigated the actual QoL and health status of the donors as well as the need for medical treatment since PBPC donation by a questionnaire that was sent to 151 donors. Ninety-five (64%) of the addressed donors responded to the questionnaire, but only 69 (46%) of them reported on their actual health status and QoL, which was good to very good in the majority of them. Two donors developed malignancies in the post-donation course. In general, PBPC collection after rhG-CSF mobilization was well tolerated by the responding donors. Although the reported events in medical history after PBPC donation do not seem to be associated with rhG-CSF administration or the collection procedure, a lifelong follow-up of donors should be obligatory.
Introduction
Fifteen years ago, the first allogeneic PBPC transplantation with recombinant human G-CSF (rhG-CSF)-mobilized PBPCs was reported. 1 Since then, cytokine-mobilized PBPCs collected from healthy sibling or unrelated donors are increasingly used as stem-cell source in the allogeneic setting. 2 PBPCs have been shown to be superior to BMderived stem cells during the early post transplant course. 3, 4 The high CD34 þ cell yield in PBPC grafts significantly shortens the post transplant aplasia and the need for blood component support, especially platelets. 3, 4 Nowadays, rhG-CSF for the mobilization of PBPCs in stem-cell donors is common, but dosage and frequency of application are still inconsistent. The administration of rhG-CSF at a dose of 5 mg per kg body weight (BW) s.c. b.i.d. for 4 consecutive days was established to mobilize a sufficient amount of hematopoietic progenitor cells from the BM into the peripheral blood. 5, 6 Usually, on day 5, PBPCs are collected by an extracorporeal circulation. Both cytokine administration and harvest procedure cause unphysiological conditions in healthy individuals. The effects of rhG-CSF on peripheral blood count and leukocyte function, cytokine release and response, coagulation parameters and metabolic changes have been reviewed by Anderlini et al. (1996) . 7, 8 However limited data exist on the late effects of cytokine mobilization and PBPC collection. Recently, researchers have raised the consideration that rhG-CSF might increase the risk of malignancies in healthy donors, especially in siblings. Several donors were identified who experienced acute leukemia after rhG-CSF administration. 9, 10 Bennett et al. 11 reported two malignancies among 200 sibling donors within 5 years. An ongoing monitoring of risks, possibly associated with rhG-CSF administration to healthy donors, should be warranted. 12 Until now, there is no convincing evidence that rhG-CSF administration leads to an increased risk to develop hematological malignancies in healthy individuals. 13 The aim of our study was (1) to assess the short-term side effects of rhG-CSF administration and PBPC collection in our sibling donor population by monitoring of medical events and recording laboratory data on days 1, 7, 30 and 100; (2) to evaluate the influence of rhG-CSF and PBPC donation on health status and quality of life (QoL) assessed by a questionnaire in a cross-sectional study and (3) to investigate the long-term safety profile of rhG-CSF by evaluation of retrospective questions on intercurrent events, such as infections, occurrence of new diseases and need for new medications. þ cells per microliters were detected, PBPC collection was started immediately; otherwise, the start of collection was day 5.
Donors and methods

Donors
Collection procedures
PBPCs were harvested by large-volume leukapheresis with a continuous-flow blood cell separator. Three different devices were used depending on operational availability (CS3000 þ , Baxter Deerfield, Deerfield, IL, USA, n ¼ 9; Spectra, Cobe Laboratories Inc., Lakewood, CO, USA, n ¼ 60; or Amicus, Fenwal Europe SPRL, Mont St. Guibert, Belgium, n ¼ 102). During PBPC collection, a median of 3.4 times total blood volume (range 1.2-5.3) of the donor was processed. In all but two donors, collection was performed through peripheral venous access. Citrate (adenine citrate dextrose (ACD)-Formula A) was used for anticoagulation fluid at a ratio of 1:12. In the majority of donors, a continuous calcium infusion (2.25 mmol/h (89.4 mg)) was given. During collection, vital signs and collection-related adverse events were monitored. PBPC collection was repeated until the threshold amount of 4 Â 10 6 CD34 þ per kg body weight of the recipient was collected. However, not more than three consecutive collections were performed. To optimize donors safety, we routinely re-transfused platelet-rich plasma of the PBPC product in case of a post-donation platelet count below 80 g/l or if a second or third donation was necessary, and the post-donation platelet count was below 100 g/l.
Details of PBPC collection are given in Table 1 .
Laboratory analysis
Peripheral blood and differential counts were monitored during and after PBPC collection. All donors were asked to come for regular follow-ups on days 1 and 7, after 1, 3 and 12 months and then on a yearly basis. For follow-up, peripheral blood and differential counts were assessed by Cell Dyn 3500 À (Abbott Diagnostics, South Pasadena, CA, USA). CD34 þ cells were measured according to the ISHAGE protocol with a dual-laser FACSCalibur (Becton Dickinson, San Jose, CA, USA) using CellQuest software. 14, 15 Questionnaire The questionnaire, covering specific health problems and new medications since PBPC donation, was sent to 151 of 171 donors at a median of 4 (range, 0.2-11) years after donation. In 20 donors, the actual address was unknown.
Donors were asked to report side effects of rhG-CSF and PBPC donation retrospectively. They were also asked to judge their general health condition and QoL from very good to very poor on a modified visual analog scale. Scores were linearly transformed to a 0 (very poor) to 100 (very good) scale. In addition, they were requested to indicate the influence of the whole procedure on their further QoL on a scale from negative (À50) through no influence (0) to positive (50).
Statistical analyses
Results are expressed as median and range for descriptive purposes in the text. Because of the non-normal distribution of data, all comparisons were made by non-parametric statistics. Statistical analyses were performed by using the Mann-Whitney U-test. A two-tailed P-value of o0.05 was considered significant and, if appropriate, the Spearman rank correlation test and the w 2 test were applied. A P-value of o0.05 was considered significant.
Results
CD34 mobilization and harvest procedures
We observed a significant lower CD34 þ mobilization capacity in females (median 0.1% CD34 þ cells, range 0.03-0.4%) than that in male donors (median 0.15% CD34 þ cells, range 0.04-0.36%), leading to a significant lower absolute CD34 þ cell count in females (Po0.05). Interestingly, in our cohort, donor age had no influence on the amount of mobilized CD34 þ cells in both males and females (P ¼ 0.25, R 2 ¼ 0.004), but we observed a trend to a positive correlation between mobilization of WBCs and donor's age only in males (data not shown).
In the majority (123/171, 72%) of donors, one collection procedure was sufficient to achieve the required CD34 þ cell Table 1) .
Follow-up of laboratory parameters
The compliance for follow-up decreased over time irrespective of the donor's age or gender. This was, on the one hand, probably due to residences far away from our collection center, but on the other, we noticed a correlation of willingness for follow-up and the outcome of the recipient. We therefore reviewed peripheral blood counts only till day 100, which was kept by 41 donors. For the 1-year follow-up, 23 of 154 donors (15%) were available, and 5 years after donation only 2 of 81 eligible donors had a laboratory check ( Figure 1 ). Our observations concerning the post-donation course of peripheral blood and differential counts were in line with earlier reports. [16] [17] [18] [19] Day 100 of follow-up revealed normal WBC counts in nearly all evaluable donors (median 5.9 g/l, range 3-8.8). At this time, the relative lymphocyte count was normal in the investigated subjects (data not shown).
Platelet loss during the collection procedure depended on the cell separator used. The lowest platelet loss was observed with the Amicus device, median 19% (range, 1-53%) and the highest with Spectra, median 53% (range, 3-69). In 15 of these donors, who donated on Spectra, platelet-rich plasma from the PBPC products was retransfused because of a post-donation count of o80 g/l (n ¼ 10) or o100 g/l and there was need for further donations (n ¼ 5).
Short-term events
Adverse events occurring within 30 days after mobilization and PBPC collection were defined as short-term events.
Two donors had to be hospitalized after donation. A 67-year-old female donor, who donated for her sister (diagnosed with multiple myeloma), experienced severe enteritis 1 day after collection. She was dismissed 2 days later in good clinical condition. Her sister showed no complications during the early post transplant course. Another female donor (39 years) who underwent two collection procedures was diagnosed with a subdural hemorrhage 2 weeks after donation. A trepanation had to be performed, and she recovered without a neurological deficit. It can be noted that her platelet counts were always above 150 Â 10 9 /l during mobilization, stem cell collection and in the post-donation course. She had normal coagulation parameters and did not receive any medication with platelet aggregation-inhibiting capacity.
Retrospective assessment of health problems after PBPC donation by Questionnaire Of 151 donors, 95 (63%) responded to the questionnaire. From 56 donors (37%), who did not respond, the address had changed in 11 subjects, whereas in 24 cases, the intended recipient was already dead at the time of the survey and 2 donors had died.
One male donor (51years), who was a heavy smoker, died 6 months after PBPC donation because of squamous cell cancer, which was not known at the time of PBPC donation. His brother, diagnosed with multiple myeloma, had an uneventful early post transplantation course and died 4 years later of his underlying disease. The other donor (male 49 years) developed acute renal failure because of generalized diabetic vasculopathy 14 months after donation and subsequently died. One male donor (29 years) was diagnosed with Hodgkin's disease 1 year after donation for his sister, who suffered from non-Hodgkin's lymphoma.
A positive medical history was reported in 34 of 95 donors (36%), and the onset of medical treatment after PBPC donation in 16 of them. Data are shown in Tables 2a  and b. No evidence of the increased occurrence of infections, need for surgical interventions or development of malignancies was observed in the responding group. Cardiac and metabolic disorders as well as hypertension and the need for medical treatment occurred predominantly in the elderly. It can be noted that 47 of 171 donors (27%) were X50 years at the time of PBPC donation.
However, because of the considerable percentage of no responses (37%), there may be an estimated number of unreported cases of malignancies or long-term adverse events.
Adverse events of rhG-CSF administration and stem cell collection (retrospective assessment) Only 70 of 95 donors stated side effects of rhG-CSF. Of these, 40 donors (61%) reported side effects, such as myalgia and headache (76%), flu-like symptoms (28%) and fatigue (12%).
Sixty-seven donors (73%) responsed concerning the side effects of PBPC collection. Eighteen (27%) reported adverse events that were classified as citrate reaction (n ¼ 13), fatigue (n ¼ 5) and headache (n ¼ 2). 
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In general, both rhG-CSF administration and the collection procedure were tolerated well. A minority of donors reported poor tolerance to the whole procedure (Figure 2a) . Interestingly, side effects of the PBPC mobilization or the collection procedure were not mandatorily associated with poor tolerance to the whole procedure. In addition, death of the PBPC recipient (n ¼ 15) did not negatively influence the rating of these donors who responded to the questionnaire.
Influence of rhG-CSF and PBPC donation on health status and QoL
The majority of the responding donors reported a positive or no influence of rhG-CSF and donation on their general condition. Only two and three patients reported a negative influence of rhG-CSF and PBPC donation on their health status and QoL, retrospectively (Figures 2b and c) . The actual health status and QoL were reported to be good to very good in nearly all of the responding donors.
Discussion
In this study, we investigated adverse events related to rhG-CSF administration and PBPC collection in sibling donors as well as the influence of rhG-CSF and donation on their health status and QoL by a cross-sectional study.
Owing to the superiority of rhG-CSF-mobilized PBPC versus BM transplantation (fast cell recovery, less need of blood component support and GvL effect) PBPCs are used preferably in the allogeneic transplant setting although, there is still uncertainty concerning the impact of GvHD, which is more common after PBPCT than after BMT, on the outcome of the patients. [20] [21] [22] However, administration of rhG-CSF leads to high serum levels in individuals, exceeding endogenous G-CSF levels measured under physiological and pathophysiological conditions, leading to adverse events in a number of them. 7 In contrast to BM, which is collected under general anesthesia by multiple aspirates from the iliac crest, a good peripheral venous access is a requirement for successful PBPC collection. Only 2 of our 171 female donors (1, 1%) needed central venous access for PBPC collection, and thus were exposed to the well-known risks of arterial puncture, pneumothorax and venous thrombosis. Complications owing to the central venous catheter are reported to occur in 1-9% of individuals depending on the localization of access. [23] [24] [25] To avoid these risks, BM instead of PBPC donation could be considered in donors with insufficient peripheral veins.
As published earlier, CD34 þ harvest results correlate strongly with the amount of CD34 þ cells in peripheral blood. 3, 26 Beside recipient variables (for example, body weight and required CD34 amount), the concentration of CD34 þ cells in the peripheral blood of donors is predictive for estimation of the number of procedures. 26 In line with earlier observations, we found a significantly lower CD34 þ cell concentration in the products of female than that in male donors, irrespective of the donor's age (Po0.05). 3, 26 In our study, we could not confirm the observation of Suzuya et al. 27 who found a negative correlation between donor's age, CD34 mobilization capacity and yield. This can be best explained by the fact that the investigated cohort of donors in our study was older than the donors described by Suzuya et al., 27 with a median age of 41 years (range 11-72), and only two were younger than 18 years. Of 56 donors, 30 were below 18 years, and therefore the impact of donor's age probably was not detectable in our cohort. Shimizu et al. 28 described this phenomenon only in female donors.
The loss of up to 50% of platelets during PBPC collection is well known. 16, 17, 19, 29 We recorded an almost negligible 
Table 2a
Reported events and health impairment in PBPC donors (n ¼ 33 of 95)
Flu-like syndromes (n ¼ 5) Coronary artery bypass graft (n ¼ 1)
33 donors reported 42 medical events.
Follow-up of stem cell donors GC Leitner et al loss of platelets if the Amicus device was used (median 19%). Using this device, further manipulations to remove platelet-rich plasma from the product can be avoided, and thus the safety of the donor and the product safety can be increased. In none of the 102 siblings (59%) who donated on the Amicus did the platelet counts decline below 80 g/l after donation and only 2 donors had a post-donation platelet count below 100 g/l. In contrast, 10 of 60 donors (16%) on the Spectra had a post-donation platelet count of o80 g/l, and in 17 of 60 donors (28%), the platelet counts ranged between 80 and 100 g/l after donation. During the harvest procedure, donors were exposed to a remarkable amount of ACD-A (mean 1260 ml, ±308), which is about three-fold higher than in platelet apheresis, resulting in a transient but clinically relevant loss of ionized calcium. By implementing a continuous calcium infusion during PBPC collection, citrate toxicity was kept low. Only 9% of the donors reported citrate reactions.
According to an investigation by Platzbecker et al., 30 a significant but asymptomatic spleen enlargement owing to cytokine administration has to be expected in all PBPC donors. In five cases, splenic rupture has been described as occurring on day 6 in four cases and on day 5 in one case of mobilization. 31, 32 Risk factors were high dosage of rhG-CSF (410 mg/kg) combined with prolonged administration (6 days) and/or WBC counts about 80 g/l.
31,33 Therefore, we decided to monitor blood cell counts and CD34 þ cells since day 4 of mobilization and to start with PBPC collection when WBC count exceeded 70 g/l or more than 50 CD34 cells per microliter were measured.
We recorded two serious events in the early postdonation period: One female donor developed severe enteritis 2 days after donation with the need for hospitalization unlikely to be caused by rhG-CSF administration and PBPC donation. Another female donor was diagnosed with a subdural hemorrhage 2 weeks after PBPC donation. To our knowledge, no reports exist that describe cerebral bleeding events in healthy individuals with normal platelet counts after extracorporeal circulation when citrate is used for anticoagulation. At the time of our survey, we were informed by the transplantation unit that two donors were deceased, one of acute renal failure caused by generalized diabetic vasculopathy and the other caused by squamous cell cancer of the tongue. One donor developed Hodgkin's disease 1 year after donation and is still alive 3 years after diagnosis. Reports on malignancies after rhG-CSF administration in healthy individuals are still anecdotal, and in most cases a genetic risk may be present as donors experienced the same malignant entity as their siblings. 9, 11 In a small study, Nagler et al. 34 observed epigenetic changes in lymphocytes of healthy individuals after rhG-CSF administration, which were similar to those seen in cancer patients. The compliance of donors for follow-up was rather low in our sibling donor population, probably because of residences being far away from the donation center or because of the death of the relatives for whom they donated. The latter was also observed in the frequency of responses to the questionnaire. In 63% of missing responses, the recipient had died, whereas in the responding group only 16% of the recipients were dead. The laboratory results of our donors during the early post-donation course regarding WBC and platelet counts were in line with earlier reports. 1, [16] [17] [18] [19] 29 Our questionnaire included the history of intercurrent diseases, surgical interventions and the need for new medications in the post-donation period. Most events occurred in donors who were 50 years of age and older at the time of query. The described events are common in a cohort at this age, such as the development of hypertension, coronary heart disease, metabolic disorders or surgical intervention. Therefore, the need for antihypertensive medications, cholesterol lowering and antidiabetic drugs were almost predictable in these cases. Donors younger than 50 years mostly reported common infections and orthopedic surgeries because of sports-related injuries.
Lacking a control cohort of siblings who did not donate stem cells, we compared the data of our donors regarding the incidence of infections, cardiac, endocrine and hematological disorders as well as surgical intervention and the necessity for medications with the microcensus crosssectional investigation of 'Statistik Austria' in the year 1999. The microcensus investigation is a measure of the Austrian government to evaluate epidemiological and demographic data. A total of 7.958 individuals ranging between o1 year and 74 years of age were evaluated and revealed comparable results. 35 As no increased risk of health impairment was observed in allogeneic stem cell donors vs 'non-donors,' as reflected by the microcensus investigation, we presume that a control group of 'nondonors' would reveal similar results.
In summary, rhG-CSF mobilization as well as subsequent PBPC collection is shown to be well tolerated in the short-and long-term profiles in our cohort of sibling donors and had no negative influence on health status and QoL in the majority of them. We observed no increased risk for hematological or oncological disorders. However, to acquire profound knowledge about rhG-CSF-and donation-related long-term risks, consecutive monitoring of more donors for at least 10 years has to be performed. Hasenclever and Sextro 36 stated that to exclude or to show a 10-fold increase in the 10-year cancer incidence, a longterm prospective follow-up of several thousand donors for at least 10 years would be necessary.
Therefore, we recommend a lifelong prospective followup in a centralized data collection system enabling analysis of a large cohort of donors.
